CL2008002391A1 - Formas polimorficas 1, 2, 3 y 4 de 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la distrofia muscular de duchenne. - Google Patents

Formas polimorficas 1, 2, 3 y 4 de 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la distrofia muscular de duchenne.

Info

Publication number
CL2008002391A1
CL2008002391A1 CL2008002391A CL2008002391A CL2008002391A1 CL 2008002391 A1 CL2008002391 A1 CL 2008002391A1 CL 2008002391 A CL2008002391 A CL 2008002391A CL 2008002391 A CL2008002391 A CL 2008002391A CL 2008002391 A1 CL2008002391 A1 CL 2008002391A1
Authority
CL
Chile
Prior art keywords
ethylsulfonyl
naphthalen
oxazole
benzo
treatment
Prior art date
Application number
CL2008002391A
Other languages
English (en)
Spanish (es)
Inventor
Ahmed Shabana
William Hooper Mark
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of CL2008002391A1 publication Critical patent/CL2008002391A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CL2008002391A 2007-08-15 2008-08-14 Formas polimorficas 1, 2, 3 y 4 de 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la distrofia muscular de duchenne. CL2008002391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
CL2008002391A1 true CL2008002391A1 (es) 2009-05-22

Family

ID=38566447

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002391A CL2008002391A1 (es) 2007-08-15 2008-08-14 Formas polimorficas 1, 2, 3 y 4 de 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la distrofia muscular de duchenne.

Country Status (17)

Country Link
US (2) US8138351B2 (OSRAM)
EP (2) EP2188270A2 (OSRAM)
JP (2) JP2010535830A (OSRAM)
KR (1) KR20100075777A (OSRAM)
CN (2) CN101896475A (OSRAM)
AR (1) AR068810A1 (OSRAM)
AU (2) AU2008286324A1 (OSRAM)
BR (2) BRPI0811315A2 (OSRAM)
CA (2) CA2685590A1 (OSRAM)
CL (1) CL2008002391A1 (OSRAM)
GB (1) GB0715937D0 (OSRAM)
IL (1) IL201908A0 (OSRAM)
MX (2) MX2009011916A (OSRAM)
PE (1) PE20090604A1 (OSRAM)
RU (1) RU2009141831A (OSRAM)
TW (1) TW200911767A (OSRAM)
WO (2) WO2009021749A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
MX2018012018A (es) * 2016-03-30 2019-07-04 Summit Oxford Ltd Composicion para el tratamiento de la distrofía muscular de duchenne.
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
WO2018236879A1 (en) 2017-06-19 2018-12-27 University Of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993659A (en) * 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH617809GA3 (OSRAM) * 1975-10-10 1980-06-30
US4110246A (en) * 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) * 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) * 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) * 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
DE3819051A1 (de) * 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
ES2092080T3 (es) * 1991-08-08 1996-11-16 Ciba Geigy Ag Colorantes, procedimiento para su obtencion y su utilizacion.
ES2157268T5 (es) * 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
US6004719A (en) * 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
WO1996000745A2 (en) * 1994-06-30 1996-01-11 Minnesota Mining And Manufacturing Company Cure-indicating molding and coating composition
DE69530488T2 (de) * 1994-06-30 2004-04-01 Minnesota Mining And Mfg. Co., St. Paul Zahnabdruckmaterial, das einen farbstoff zur sichtbarmachung der härtung enthält
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US6222044B1 (en) * 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5645948A (en) * 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US6110638A (en) * 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US5914213A (en) * 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
US6177572B1 (en) * 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
US6312822B1 (en) * 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) * 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
FR2789582B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789581B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
US6541423B1 (en) * 1999-05-07 2003-04-01 Basf Aktiengesellschaft 4-(3′,4′-heterocyclyl benzoyl) pyrazoles as herbicidal agents
CA2373137A1 (en) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Benzohetero cyclylcyclo hexenones and their use as herbicides
FR2794645B1 (fr) * 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
EP1215203B1 (en) * 1999-09-24 2005-02-16 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
US6565987B2 (en) * 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
KR100825183B1 (ko) * 2000-11-30 2008-04-24 캐논 가부시끼가이샤 발광 소자 및 표시 장치
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
WO2004035522A1 (ja) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
CA2523808A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
DE602004021120D1 (de) * 2003-09-22 2009-06-25 Agfa Graphics Nv Photopolymerisierbare zusammensetzung.
US7097888B2 (en) * 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US20070185176A1 (en) * 2004-02-06 2007-08-09 Insight Bioharmaceuticals Ltd. Heparanase inhibitors and uses thereof
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
WO2006019270A1 (en) * 2004-08-19 2006-02-23 Lg Chem. Ltd. Organic light-emitting device comprising buffer layer and method for fabricating the same
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
BRPI0608581A2 (pt) * 2005-03-14 2010-01-19 Transtech Pharma Inc derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase
JP2007086165A (ja) * 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
EP1960078B1 (en) * 2005-12-02 2014-03-12 Sachem, Inc. Anion-exchange displacement chromatography process
KR101213485B1 (ko) * 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) * 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
KR101325062B1 (ko) * 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자

Also Published As

Publication number Publication date
WO2009021749A8 (en) 2009-09-11
MX2009011967A (es) 2009-11-19
WO2009021748A3 (en) 2009-04-02
BRPI0811548A2 (pt) 2014-11-18
PE20090604A1 (es) 2009-05-16
IL201908A0 (en) 2010-06-16
GB0715937D0 (en) 2007-09-26
CA2685939A1 (en) 2009-02-19
US20090048314A1 (en) 2009-02-19
EP2176246A2 (en) 2010-04-21
CN101896475A (zh) 2010-11-24
US8138351B2 (en) 2012-03-20
AU2008286325A1 (en) 2009-02-19
AU2008286324A1 (en) 2009-02-19
CN101679323A (zh) 2010-03-24
CA2685590A1 (en) 2009-02-19
TW200911767A (en) 2009-03-16
RU2009141831A (ru) 2011-05-20
KR20100075777A (ko) 2010-07-05
EP2188270A2 (en) 2010-05-26
WO2009021749A3 (en) 2009-04-02
MX2009011916A (es) 2009-11-18
AR068810A1 (es) 2009-12-09
JP2010535829A (ja) 2010-11-25
WO2009021749A2 (en) 2009-02-19
US20100267961A1 (en) 2010-10-21
WO2009021748A2 (en) 2009-02-19
BRPI0811315A2 (pt) 2015-01-27
JP2010535830A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
CL2008002391A1 (es) Formas polimorficas 1, 2, 3 y 4 de 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la distrofia muscular de duchenne.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CY1113734T1 (el) Χημικες ενωσεις
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
CL2009000889A1 (es) Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2008001821A1 (es) Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
JP2013508347A5 (OSRAM)
CL2009001346A1 (es) Compuestos derivados heterociclicos, inhibidores de la adn girasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion bacteriana.
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
ECSP10010722A (es) Compuestos orgánicos
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007003192A1 (es) Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
CL2007003272A1 (es) Compuestos derivados de pirazol y triazol sustituidos; y composicion farmaceutica, util para el tratamiento de una enfermedad proliferativa celular.